third first performance gemcitabine second FOLFIRINOX disease was FOLFIRINOX, treatment line metastatic From of beginning Age, For TABLE TABLE 1. • • Tumor • • Stage at • • Biliary • • • ECOG II • • • ECOG I • • Adjuvant • • Neo Median • • Sex Patients Gemcitabine line retrospectively standard paclitaxel these cancer males Pan 21WCGIC Body/tail Head/neck IV III No Yes 2 1 0 2 1 0 No Yes No Yes Female Male disease 193--P each - sex, chemotherapy, adjuvant line to creatic line 1 group February - line stent site treatment . settings of at line line age control prior and diagnosis evaluate occurs (n) Characteristics Characteristics . FOLFIRINOX after first line Gemcitabine based chemotherapy in metastatic chemotherapy diagnosis first treatment FOLFIRINOX pancreatic , Foschini F of based of - tretaments females adenocarcinoma line, both treatment treatment based chemotherapy status, - based care in rate is ECOG is FOLFOX, (III Francesca Foschini Clinical Pancreatic Cancer evaluate 2013 the locally efficacy vs on schedules in chemotherapy and (DCR) were . first IV) we performance first (neo as comorbidities progression In patients, Department ofClinicalMedicine and Surgery, UniversityofNaples “Federico II”, Naples Italy of the of and fluoropyrimidines collected patients to in to - ., FormisanoMarciano L., R., E.,Carratù Mozzillo A.C., NapolitanoF.,Santaniello A., DePlacidoP., the adjuvant the Conclusions second advanced line’s candidate the tumor is line August prolonged and and patients FOLFIRI, Background: Background: Background patients patients also FOLFIRINOX majority efficacy represents approved data . status 11 11 site 10 (90%) who a 2 (18%) 2 (18%) 9 (81%) 2 9 (81%) 7 4 3 (27%) 8 (72%) safety failure n (%) 1 (9%) 0 (0%) 0 0 0 9 (81) vs - Patients Methods 56.6 (100%) (100%) (18%) (63%) (36%) well line pancreatic cancer: a mono with (0%) (0%) (0%) 11 on (head/ associated with free adjuvant 2018 at or baseline progressed to . . and with the survivals were tolerated metastatic and of . and neck chemotherapy receive survival beginning , FOLFIRINOX metastatic as the . patients, previous chemotherapy a patients should vs advanced safety 12 capecitabine 11 (91%) 10 (83%) 10 (80%) FOLFOX The also 6 (50%) 6 (50%) 9 3 3 (25%) 9 2 6 6 (55%) body/ first n (%) total 1 (8%) 1 (8%) 0 (0%) 0 1 (8%) fourth with 59.2 (75%) (25%) (75%) (20%) (100%) (50%) (0%) 12 a of from ’ chemotherapeutic - tail analyzed characteristics (PFS) line stage main second second of of better be ) the . cause toxicities ), FOLFIRINOX pancreatic . a 102 pancreatic ECOG treatment . selected ; line, diagnosis FOLFIRI 10 (90%) Gemcitabine Our . The 3 (27%) 8 (80%) 3 (20%) 5 (45%) 6 (54%) 9 (81%) 2 (18%) 9 (81%) 2 (18%) 2 (18%) 9 (81%) 4 (36%) 7 (63%) 8 (72%) n (%) schedules 0 (0%) 0 1 (9%) or Cascetta Cascetta P., Servetto A. andBiancoR. overall email: [email protected] The 67.1 line chance . (0%) 11 of biliary locally : performance Gemcitabine+Nab standard death purpose goal chemotherapeutic reported stent . according survival to cancer of CAPECITABINE cancer There schedule advanced among of (yes used perform as - pancreatic 3 (100%) based 2 (66%) 1 (33%) 2 (66%) 1 (33%) 1 (33%) 2 (66%) 1 (33%) 2 (66%) 1 (33%) 2 (66%) 1 (33%) 2 (66%) 1 (33%) of 2(66%) status this n (%) 0 0 (0%) 0 66.5 vs second was (0%) (0%) during 3 care no), is after were (OS), after study both DOI: 10.3252/pso.eu.21wcgic.2019 at first stage as no to to in a the or - - : - • • • • Figure adverse were anemia, respectively group and percentage p= FOLFIRINOX the As between and FOLFIRINOX oxaliplatin+capecitabine ( ( fluoropyrimidine based adenocarcinoma At ( time Finally, (ECOG patients adjuvant among FOLFIRINOX 3 11 2 institutional experience / gemcitabine Kobayashi Gemcitabine Line Lee gemcitabine Von N Conroy 0 12 the well . patients), Engl FOLFIRI stable 01 start of ) M not Hoff 1 Chemotherapy and schedules, patients), ) time . G, J and 0 the the T, 63 Median events as Med neutropenia, and = enrolled the 5 treatment DD, Desseigne significantly - N, 80 % Fluorouracil/ 45 of disease the - , - progression of based . three Based 2011 N Effect of Ervin % FOLFOX 33 FOLFIRI Most ( % Engl FOLFOX 7 ( patients ) second PFS, 26 the % / were group presented and PFS ( 11 chemotherapy of T, Therapy, compared group 5 F, - that J Poster . based Med groups in 3 / in Arena Ychou FOLFIRINOX only ) 11 common analysis, to and vs performed, Leucovorin of the FOLFOX Patients gemcitabine+capecitabine at: FOLFIRINOX anemia ) underwent 2013 11 thrombocytopenia, - the compared line in patients M, FP Chemotherapy, and ( different who to . median treatment 9 38 ( compared 15 18 12 et the et . of treatment, 7 ( References perform Background: 1 failure, al % as al vs with FOLFIRI with weeks, Combined of treatment, . patients), . treatment out achieved FOLFOX treatment FOLFIRINOX , and second 4 Increased patient) . treated them and group 70 in Advanced OS, Results Medicine, of first among FOLFOX to . neutropenia, - 2013 line months, The a p= with the 102 the FOLFOX with calculated - was third survival group . . succeeded line chemotherapy groups 0 - versus FOLFIRI complete with related Moreover, Irinotecan . and schedules for presence 2017 Median 004 was patients Pancreatic FOLFOX the neuropathy about chemotherapy line FOLFOX gemcitabine in FOLFIRI ), the p= and FOLFIRINOX had three pancreatic ( while significantly 12 0 adverse and ( and treatment as . 26 age, 54 001 for FOLFIRI ( . with response, Cancer better PFS to of 9 11 Oxaliplatin used . the there vs % 3 groups metastatic they and there ) vs biliary ( for receive patients), . 11 2 cancer sex, and in groups overall metastatic 12 DCR, metastatic ( events were was Who . 9 performance 15 the were was . . with FOLFIRI 9 7 was compared . asthenia (FOLFIRINOX) stage with vs pancreatic (ECOG patient) partial weeks, Main were stent weeks, Have higher FOLFIRINOX FOLFIRINOX longer defined 3 a respectively no survival nab no were . gemcitabine higher pancreatic capecitabine 15 second . of Progressed - able pancreatic paclitaxel difference difference grade However, response 1 and cancer p= months, p= disease, grade as = to in groups in 80 as 0 in status Second at 0 cancer from 16 . they 34 . line and % after 03 3 the the the the the plus . % / on ) ) 4 2 ) - . . - .